Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook [Yahoo! Finance]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Yahoo! Finance
Test Volume Increase : The company saw a 24% increase in total test volume for the year, indicating strong demand for its diagnostic products. Operational Cash Flow : Veracyte generated $44 million in cash from operations and ended the year with $216 million in cash and cash equivalents. Net Loss : Despite revenue growth, the company recorded a net loss of $74.4 million for the year, including significant impairment charges. 2024 Outlook : Veracyte maintains its total revenue guidance for 2024, projecting between $394 million to $402 million. Warning! GuruFocus has detected 1 Warning Sign with VCYT. On February 22, 2024, Veracyte Inc ( NASDAQ:VCYT ), a leading genomic diagnostics company, released its 8-K filing , announcing financial results for the fourth quarter and full year ended December 31, 2023. The company, known for its genomic diagnostic products and services aimed at improving patient care for diseases such as thyroid cancer, lung cancer, and idiopathic pulmonar
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN [Yahoo! Finance]Yahoo! Finance
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024Business Wire
- New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance [Yahoo! Finance]Yahoo! Finance
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceBusiness Wire
- CareDx appoints John Hanna as president and CEO [Seeking Alpha]Seeking Alpha
VCYT
Earnings
- 2/22/24 - Miss
VCYT
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- VCYT's page on the SEC website